Johnson & Johnson (JNJ) is back in focus after new clinical analyses at the TCT 2026 symposium linked its Impella heart pumps to lower in-hospital and short term mortality in high risk coronary procedures.
After the latest Impella data hit the TCT stage, Johnson & Johnson's momentum has been firm, with a 30-day share price return of 6.71% and a year-to-date share price gain of 31.76%. A 1-year total shareholder return of 49.98% and a 3-year total shareholder return of 96.12% point to longer term compounding as MedTech and oncology updates, plus steady ETF inflows, keep interest in the stock elevated.
Scan 29 resilient stocks with low risk scores to see how other resilient healthcare and MedTech players compare with Johnson & Johnson after this latest Impella update.
Johnson & Johnson looks like a powerhouse on the product and dividend fronts, and the recent Impella driven rally underlines that. The real question is whether that strength is already fully reflected in the US$273 share price.
Most Popular Narrative: 14% Overvalued
On Simply Wall St, the most followed narrative pegs Johnson & Johnson's fair value at $240.69, which sits below the last close at $273.20. That gap frames the current Impella optimism as already priced in according to LunaRodas, who has tracked the gap between what management says and what it actually reports.
Abiomed moved from a defended narrative to a managed one. Three months ago, three executives, including the CEO himself, built a layered defense around a single overseas study: 300 patients, questioned methodology, a near-term dynamic set against tens of thousands of patients studied and hundreds of thousands of lives supported. Now the same company, managing a decline management itself concedes is still ongoing, gets one paragraph from one executive. No CEO intervention. No tally of supporting publications. The confidence language survives almost verbatim. The defensive architecture around it does not.
See why 4 investors see Johnson & Johnson as 14% overvalued .
Result: Fair Value of $240.69 (OVERVALUED)
Still, the current Johnson & Johnson story leans heavily on MedTech execution and consistent communication from management, and any renewed Abiomed weakness or narrative shift on double digit growth targets could challenge that fair value view.
Find out about the key risks to this Johnson & Johnson narrative .
Another View: Johnson & Johnson Through The Market's Lens
There is a split screen on Johnson & Johnson. While the most followed narrative tags the shares as 14% overvalued against a $240.69 fair value, our SWS fair ratio work tells a different story. At a P/E of 40.9x, the stock sits below a fair ratio of 46x and well under a 62.5x peer average, yet trades far richer than the wider US Pharmaceuticals group at 16x. That mix of premium to the sector and discount to close comparables leaves an awkward question for investors. Is the real risk that sentiment compresses toward the industry, or that valuation stretches back toward the fair ratio and peer levels instead?
For a closer look at how this pricing gap lines up with earnings power and peer comparisons, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Johnson & Johnson is mixed, with strong enthusiasm and clear concern sitting side by side. Move fast and weigh the evidence yourself using 3 key rewards and 3 important warning signs
Looking for more investment ideas beyond Johnson & Johnson?
If you only stop at Johnson & Johnson, you risk missing opportunities that better fit your goals, risk comfort, and income needs across the wider market.
-
Target dependable balance sheets by scanning a list of solid balance sheet and fundamentals (24 results) that filters for companies built on stronger financial foundations.
-
Hunt for potential mispricing and compare alternatives to Johnson & Johnson through a curated 36 high quality undervalued stocks that highlights quality businesses trading below estimated worth.
-
Strengthen your income stream by reviewing a focused 5 dividend fortresses packed with higher yielding payers that may complement a holding like Johnson & Johnson.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include JNJ .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
